Group 1 - The core viewpoint of the article highlights the recent stock performance of WuXi Biologics, which saw a decline of 2.02% to 31.55 CNY per share, with a trading volume of 900 million CNY [1] - WuXi Biologics is recognized as a leading global provider of biologics services, offering comprehensive and highly customized services throughout the entire process from discovery and development to production [1] - The company held a significant market share of 48% in China's biologics R&D market in 2016 and has established partnerships with 12 out of the top 20 global pharmaceutical companies [1] Group 2 - As of the 2024 annual report, WuXi Biologics reported total revenue of 18.675 billion CNY and a net profit of 3.356 billion CNY [2] - The company is scheduled to disclose its mid-year report for the fiscal year 2025 on August 19 [2]
药明生物(02269)下跌2.02%，报31.55元/股